跳至主要内容
临床试验/NCT05571514
NCT05571514招募中不适用

Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis: Multicentre, Double-blind Randomized Versus Positive Comparator Study

Centre Hospitalier Universitaire de Saint Etienne9 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
9
主要终点
Change in bone loss at lumbar site

研究概览

简要总结

Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality.

Given potential side effects, hormone replacement therapy is no longer recommended for menopausal women with risk of becoming osteoporotic. The very significant decrease in the use of these treatments is suspected of contributing to a resurgence in the incidence of osteoporotic fractures, particularly in women before the age of 70. There is a need for prevention of osteoporosis.

详细描述

Mother-of-pearl is a candidate for long-term use due to the combination of its effects: calcium supplementation, anti-resorptive activity and osteoanabolic activity.

Our hypothesis is that powdered mother-of-pearl supplementation limits bone loss in postmenopausal women with risk of becoming osteoporotic.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Stratified randomization :

The study will be double-blinded to avoid follow-up bias and assessment bias. The maintenance of the blind will be guaranteed by the fact that the capsules of mother-of-pearl will be indistinguishable from those of CaCO3 (same shape, same color, same weight). Only the internal use pharmacies (IUP) of each center will be open, for the attribution of the treatment.

入排标准

年龄范围
50 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Post-menopausal women (50-65y) with risk of becoming osteoporotic
  • T-score between -1 and -3
  • Absence of fragility fractures history

排除标准

  • absence of parathyroid glands (phospho-calcic regulation)
  • presence of kidney stones
  • patients who follow a treatment that could interfere with bone metabolism (corticotherapy, menopausal hormonal therapy, anti-oestrogen treatment, non-controlled hyperthyroiditis, hyper- and hypothyroiditis)
  • bone diseases (Paget'disease, osteomalacia)
  • chronic alcoholism

结局指标

主要结局

Change in bone loss at lumbar site

时间窗: Baseline from 12 months

Demonstrate that oral mother-of-pearl powder supplementation, for 1 year, reduces bone loss at lumbar site in postmenopausal women with risk of becoming osteoporotic, in a better way than oral supplementation with pure CaCO3. Measurement of the change in BMD will be performed by DXA (dual X-ray absorptiometry bone densitometry)

次要结局

  • Change in bone remodeling of the femur(Baseline from 12 months)
  • Tolerance to oral mother-of-pearl powder supplementation(Baseline from 12 months)
  • Change in bone loss at the upper end of the femur(Baseline from 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验